Loading organizations...
Galatea Bio has raised $8.0M across 1 funding round.
Key people at Galatea Bio.
Galatea Bio has raised $8.0M in total across 1 funding round.
Based in Miami, Florida, United States, Galatea Bio is a biotechnology company that builds a global biobank focused on underrepresented populations to address ethnic biases in genetic research datasets. The organization pairs genetic diversity with ancestry-informed analytics and multimodal data to accelerate precision medicine discoveries for its biopharma partners. Galatea Bio provides access to comprehensive data on approximately 10 million patients, offering critical insights for the genomics and pharmaceutical sectors. The enterprise is supported by venture capital and government grants, recently securing $25 million in funding during March 2025 to further expand its biobank operations. The firm presented its research on harnessing human diversity at the PMWC 2025 Silicon Valley conference and received a federal SBIR award in 2024. The company was founded by executive researchers Carlos D. Bustamante, Nicholas Katsanis, and Alexander Ioannidis.
Galatea Bio has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series U in March 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2025 | $8M Series U | — | F Prime Capital, IFC Venture Capital Group, Pareto Holdings, Partech Ventures | Announced |
Galatea Bio has raised $8.0M in total across 1 funding round.
Galatea Bio's investors include F-Prime Capital Partners, IFC Venture Capital Group, Pareto Holdings, Partech Ventures.
Key people at Galatea Bio.
Galatea Bio is a biotechnology company founded in 2020 that leverages genetic diversity, particularly from underrepresented Latin American populations, to advance precision medicine, drug discovery, and health outcomes.[1][2] It operates through three main pillars—GB Health (clinical lab services delivering actionable results), GB Community (biobanking via the Biobank of the Americas), and GB Discovery (developing algorithms and pharmaceutical targets)—serving academic, private, pharma, and clinical partners while addressing gaps in genetic research for diverse communities.[2][4] The company has raised $3.66M in debt financing from investors like F-Prime Capital, operates a CLIA-CMS certified and CAP-accredited high-complexity lab in Miami Lakes, Florida, and recently collaborated with DNAnexus to enhance genetic tools for underserved populations.[1][4]
Galatea Bio was co-founded in 2020 by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis, experts who identified a critical gap in genetic population studies dominated by northern European data, limiting discoveries and exacerbating health disparities for underrepresented groups like Latin Americans.[2] Headquartered at 14350 Commerce Way in Miami Lakes, Florida, the company emerged amid an explosion of genomic data made cheaper and faster by tech advances, but with resources unevenly allocated.[1][2] Early focus centered on ethical biobanking and ancestry algorithms, underscored by commitments to HIPAA training and WCG-IRB oversight, with pivotal traction from building the Biobank of the Americas and recent partnerships like the August 2024 DNAnexus collaboration.[1][2]
Galatea Bio rides the precision medicine wave, capitalizing on plummeting genome sequencing costs and AI-driven ancestry analysis to democratize genetic insights beyond Eurocentric datasets.[2] Timing is ideal amid rising demands for health equity—exemplified by pandemic-exposed disparities—and regulatory pushes for diverse clinical data in drug development.[1][2] Market forces like expanding biobanks and pharma's need for novel targets favor it, as non-European studies reveal unique variants boosting drug efficacy across populations.[2] By influencing ecosystem standards for inclusive genomics, it accelerates discoveries, supports underserved communities, and shapes a more equitable biotech landscape.[1][2]
Galatea Bio is poised for expansion through lab scaling, biobank growth beyond the Americas, and pharma partnerships yielding new targets, fueled by its debt-funded momentum and score surge.[1] Trends like AI-genomics integration and global health equity mandates will propel it, potentially evolving from niche player to key enabler in diverse precision medicine.[2] As genetic data explodes, its focus on Latin American diversity positions it to bridge critical gaps, redefining health outcomes from Miami Lakes outward—turning overlooked genomes into universal breakthroughs.[1][2]
